disponibile in formato PDF - Stampa alternativa

■ Boger, D.L., Patterson, J.E., Jin, Q., “Structural Requirements for 5-HT2A
and 5-HT1A Serotonin Receptor Potentiation by the Biologically Active Lipid
Oleamide”, in: Proc Natl Acad Sci USA, vol. 95, 1998, pp. 4102-4107.
■ Breivogel, C.S., Childers, S.R., “The Functional Anatomy of Brain
Cannabinoid Receptors”, in: Neurobiol. Dis., vol. 5 (6 Pt B), 1998, pp. 417-431.
■ Bridges, D., Ahmad, K., Rice, A.S., “The Synthetic Cannabinoid WIN55,212-
2 Attenuates Hyperalgesia and Allodynia in a Rat Model of Neuropathic Pain”,
in: Br J Pharmacol, vol. 133, 2001, pp. 586-594.
■ Cabral, G.A., “Immune system“, in: Grotenhermen, F., Russo, E.B., (a cura
di), 2002, p. 285-294.
■ Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D., “Control of Pain Initiation
by Endogenous Cannabinoids”, in: Nature, vol. 394, 1998, pp. 277-281.
■ Calignano, A., et al., “Bidirectional Control of Airway Responsiveness by
Endogenous Cannabinoids”, in: Nature, vol. 408, 2000, pp. 96-101.
■ Campbell, F.A., Tramer, M.R., Carroll, D., et al., “Are Cannabinoids an
Effective and Safe Treatment Option in the Management of Pain? A Qualitative
Systematic Review”, in: BMJ, vol. 323, 2001, pp. 13-18.
■ Carlini, E.A., Cunha, J.M., “Hypnotic and Anti-epileptic Effects of
Cannabidiol”, in: J Clin Pharmacol, vol. 21(8-9 Suppl), 1981, 417S-27S.
■ Chang, A.E., et al., “Delta-9-tetrahydrocannabinol as an Antiemetic in
Cancer Patients Receiving High-dose Methotrexate. A Prospective,
Randomized Evaluation”, in: Ann Intern Med, vol. 91, 1979, pp. 819-824.
■ Chatterjee, A., Almahrezi, A., Ware, M., Fitzcharles, M.A., “A Dramatic
Response to Inhaled Cannabis in a Woman with Central Thalamic Pain and
Dystonia”, in: J Pain Symptom Managem, vol. 24, 2002, pp. 4-6.
■ Cichewicz, D.L., Martin, Z.L., Smith, F.L., Welch, S.P., “Enhancement of µ
Opioid Antinociception by Oral Delta9-tetrahydrocannabinol: Dose-response
Analysis and Receptor Identification”, in: J. Pharmacol. Exp. Ther., vol. 289,
1999, pp. 859-867.
■ Clendinning, J., “Medicinal Properties of the Cannabis Sativa”, in: Med.
Chirur. Trans. (London), vol. 26, 1843, p. 188-210.
■ Clifford, D., “Tetrahydrocannabinol for Tremors in Multiple Sclerosis”, in:
Annals of Neurology, vol. 13, 1983, pp. 669-671.
■ Consroe, P.F., et al., “Anticonvulsant Nature of Marihuana Smoking”, in:
JAMA, vol. 234, 1975, pp. 306-307.
■ Consroe, P., Snider, S.R., “Therapeutic Potential of Cannabinoids in
Neurological Disorders”, in: Mechoulam, R. (a cura di), Cannabinoids as
Therapeutic Agents, Boca Raton, CRC Press, 1986.
■ Consroe, P., Sandyk, R., Snider, S.R., “Open Label Evaluation of
Cannabidiol in Dystonic Movement Disorders”, in: Int J Neurosci, vol. 30,
1986b, pp. 277-282.
128